Fu Shou Yuan (01448.HK): High base is under pressure, but customer unit prices are strong, and subsequent improvements are worth looking forward to
Fu Shou Yuan (1448.HK): Performance falls short of expectations, focuses on product optimization and sales strategy adjustments
Fu Shou Yuan (01448.HK): High base superposition demand pressure has not been relieved; focus on product optimization and boosting
Fu Shou Yuan (01448.HK): Dividend payments exceed expectations, focus on the pace of subsequent national expansion
Fushouyuan (01448.HK): 1H24 or high base; determined to transform life science service providers
Fortune Garden (1448.HK): Performance falls short of expectations and increases dividend payment strength
Fu Shou Yuan (01448.HK): North Cemetary restoration in '23 and delayed acquisitions or falling short of expectations
Fushouyuan (01448.HK): First settled in Shaanxi; focuses on the progress of transformation into a life technology service provider
Fukushouyuan (01448.HK): Business resumed rapidly, revenue and profit increased dramatically
Fushouyuan (01448.HK): Deferred demand quickly released, endogenous epitaxial boosts company growth
Fukushouyuan (01448.HK): Accumulated and deferred demand releases strong recovery in cemetery services
Fu Shou Yuan (01448.HK) 2023 Interim Report Review: Post-epidemic recovery has clearly increased operating profit margin significantly
Fushouyuan (1448) 2023 Semi-Annual Report Review: Performance Meets Expectations, Focus on Digital Transformation
Fukushouyuan (1448.HK): Demand unleashes high performance growth
Fukujuen (01448.HK) 2022 Annual Performance Review: Steady Performance and Increased Payout Ratio
Bank Ratings | Daimo: I believe Fushouyuan's (1448.HK) stock price will be upgraded and “increased” within the next 15 days
Fushouyuan (01448.HK): H2 demand is disrupted and the pace of expansion is expected to accelerate after the epidemic
Fushouyuan (01448.HK): Optimistic about demand recovery to drive growth; focus on policies and new business developments
Fu Shou Yuan (01448.HK): The epidemic affects the pace of recovery, and the backlog of demand can be expected to be released quickly in 2023
Major Bank Ratings | Bank of America Securities: Reiterates that Fushouyuan's (1448.HK) purchase rating target price was raised to HK$9.55
No Data
No Data